Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov ID: NCT02688933

Public ClinicalTrials.gov record NCT02688933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus. Secondary Objective: To demonstrate that treatment with HOE901-U300 compared to Lantus provides: * Lower incidence rate of nocturnal symptomatic hypoglycemia; * Better glucose control coverage during the last hours of CGM before next basal-insulin dosing; * Less variability in CGM profile.

Study identification

NCT ID
NCT02688933
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Sanofi
Industry
Enrollment
638 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 5, 2016 (Actual)
Primary completion
Jun 19, 2017 (Actual)
Completion
Jun 19, 2017 (Actual)
Last update posted
Mar 28, 2022

2016 – 2017

United States locations

U.S. sites
99
U.S. states
29
U.S. cities
83
Facility City State ZIP Site status
Investigational Site Number 840-151 Little Rock Arkansas 72205 —
Investigational Site Number 840-071 Concord California 94520-2270 —
Investigational Site Number 840-149 Escondido California 92025 —
Investigational Site Number 840-004 Fresno California 93720 —
Investigational Site Number 840-110 Greenbrae California 94904 —
Investigational Site Number 840-124 La Jolla California 92037 —
Investigational Site Number 840-030 La Mesa California 91942 —
Investigational Site Number 840-044 Los Angeles California 90036 —
Investigational Site Number 840-022 Los Angeles California 90057 —
Investigational Site Number 840-129 Los Gatos California 95032 —
Investigational Site Number 840-024 Northridge California 91325 —
Investigational Site Number 840-069 Pomona California 91766 —
Investigational Site Number 840-090 Pomona California 91767 —
Investigational Site Number 840-132 Rolling Hills Estates California 90274 —
Investigational Site Number 840-130 San Jose California 95148 —
Investigational Site Number 840-055 San Ramon California 94583 —
Investigational Site Number 840-028 Santa Barbara California — —
Investigational Site Number 840-063 Tarzana California 91356 —
Investigational Site Number 840-138 Tustin California 92780-6953 —
Investigational Site Number 840-016 Ventura California 93003 —
Investigational Site Number 840-039 Denver Colorado 80209 —
Investigational Site Number 840-021 Denver Colorado 80246 —
Investigational Site Number 840-070 Denver Colorado 80262 —
Investigational Site Number 840-046 Englewood Colorado 80113 —
Investigational Site Number 840-072 Coral Gables Florida 33124 —
Investigational Site Number 840-133 Hialeah Florida 33016 —
Investigational Site Number 840-137 Maitland Florida 32751 —
Investigational Site Number 840-049 Miami Florida 33155 —
Investigational Site Number 840-076 Miami Florida 33176 —
Investigational Site Number 840-023 New Port Richey Florida 34652 —
Investigational Site Number 840-053 Ocoee Florida 34761 —
Investigational Site Number 840-112 Ormond Beach Florida 32174 —
Investigational Site Number 840-018 Palm Harbor Florida 34684 —
Investigational Site Number 840-047 Port Charlotte Florida 33952 —
Investigational Site Number 840-114 Tampa Florida 33612 —
Investigational Site Number 840-036 West Palm Beach Florida 33401 —
Investigational Site Number 840-001 Atlanta Georgia 30318 —
Investigational Site Number 840-064 Columbus Georgia 31904 —
Investigational Site Number 840-012 Lawrenceville Georgia 30046 —
Investigational Site Number 840-008 Roswell Georgia 30076 —
Investigational Site Number 840-014 Stockbridge Georgia 30281 —
Investigational Site Number 840-060 Idaho Falls Idaho 83404 —
Investigational Site Number 840-125 Arlington Heights Illinois 60005 —
Investigational Site Number 840-011 Chicago Illinois 60612 —
Investigational Site Number 840-134 Crystal Lake Illinois 60012 —
Investigational Site Number 840-002 West Des Moines Iowa 50265 —
Investigational Site Number 840-073 Wichita Kansas 67226 —
Investigational Site Number 840-062 Covington Kentucky 41011 —
Investigational Site Number 840-042 Lexington Kentucky 40503 —
Investigational Site Number 840-009 Metairie Louisiana 70006 —
Investigational Site Number 840-032 New Orleans Louisiana 70115 —
Investigational Site Number 840-054 Hyattsville Maryland 20782 —
Investigational Site Number 840-006 Rockville Maryland 20852 —
Investigational Site Number 840-157 Framingham Massachusetts 01702 —
Investigational Site Number 840-122 Waltham Massachusetts 02453 —
Investigational Site Number 840-037 Flint Michigan 48532 —
Investigational Site Number 840-067 Billings Montana 59101 —
Investigational Site Number 840-094 Lincoln Nebraska 68526 —
Investigational Site Number 840-033 Omaha Nebraska 68114 —
Investigational Site Number 840-142 Omaha Nebraska 68124 —
Investigational Site Number 840-040 Henderson Nevada 89052 —
Investigational Site Number 840-017 Las Vegas Nevada 89148 —
Investigational Site Number 840-102 New York New York 10001 —
Investigational Site Number 840-108 New York New York 10029 —
Investigational Site Number 840-109 Staten Island New York 10301-3914 —
Investigational Site Number 840-045 Greenville North Carolina 27834 —
Investigational Site Number 840-010 Morehead City North Carolina 28557 —
Investigational Site Number 840-080 Morehead City North Carolina 28557 —
Investigational Site Number 840-051 Fargo North Dakota 58103 —
Investigational Site Number 840-123 Columbus Ohio 43203 —
Investigational Site Number 840-104 Mentor Ohio 44060 —
Investigational Site Number 840-079 Norman Oklahoma 73069 —
Investigational Site Number 840-162 Bend Oregon 97702 —
Investigational Site Number 840-096 Portland Oregon 97210 —
Investigational Site Number 840-058 Chattanooga Tennessee 37411 —
Investigational Site Number 840-003 Dallas Texas 75230 —
Investigational Site Number 840-019 Dallas Texas 75231 —
Investigational Site Number 840-075 Dallas Texas 75235 —
Investigational Site Number 840-005 Dallas Texas 75246 —
Investigational Site Number 840-013 Dallas Texas 75246 —
Investigational Site Number 840-153 El Paso Texas 79925 —
Investigational Site Number 840-026 Fort Worth Texas 76132 —
Investigational Site Number 840-081 Houston Texas 77024 —
Investigational Site Number 840-160 Houston Texas 77043 —
Investigational Site Number 840-156 Houston Texas 77079 —
Investigational Site Number 840-152 Houston Texas 77089 —
Investigational Site Number 840-031 Houston Texas 77095 —
Investigational Site Number 840-140 Lufkin Texas 75904 —
Investigational Site Number 840-029 Mesquite Texas 75149 —
Investigational Site Number 840-048 North Richland Hills Texas 76180 —
Investigational Site Number 840-150 Pearland Texas 77584 —
Investigational Site Number 840-083 Murray Utah 84123 —
Investigational Site Number 840-101 Ogden Utah 84405 —
Investigational Site Number 840-097 Salt Lake City Utah 84102 —
Investigational Site Number 840-143 Bennington Vermont 05201 —
Investigational Site Number 840-056 Burlington Vermont 05405 —
Investigational Site Number 840-015 Renton Washington 98055 —
Investigational Site Number 840-074 Spokane Washington 99207 —
Investigational Site Number 840-139 Bridgeport West Virginia 26330 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02688933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 28, 2022 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02688933 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →